



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

July 12, 2021

The Manager - CRD
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001
Scrip Code: 524816

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra (E) **Mumbai 400 051**
Scrip Code: NATCOPHARM

Dear Sir,

Sub: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we are enclosing here with a disclosure of Related Party Transactions for the year ended March 31, 2021.

Kindly take the above on your records

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)

NATCO Pharma Limited

(All amounts in ₹ millions)

Related party disclosures, as per Ind AS 24

(a) Names of the related parties and nature of relationship (to the extent transactions have taken place during the year)

Nature of relationship	Names of the related parties
1. Subsidiary companies	NATCO Pharma Inc., United States of America Time Cap Overseas Limited, Mauritius NATCO Pharma (Canada) Inc., Canada NATCO Pharma Asia Pte. Ltd., Singapore NATCO Pharma Australia PTY Ltd., Australia NATCO Lifesciences Philippines Inc., Philippines
2. Step-down subsidiary company	Natcofarma Do Brasil Ltda., Brazil
3. Entities in which Directors have control or have significant influence	Time Cap Pharma Labs Private Limited NATCO Trust
4. Key management personnel ("KMP")	
Chairman and Managing Director	Mr. V C Nannapaneni
Vice Chairman and Chief Executive Officer ("CEO")	Mr. Rajeev Nannapaneni
Wholetime Director	Mr. P.S.R.K. Prasad
Wholetime Director	Mr. Lingarao Donthineni
Chief Financial Officer	Mr. S.V.V.N. Appa Rao
Company Secretary	Mr. Adinarayana M
5. Non-Executive Directors and Independent Directors	
Independent Director	Mr. Sreerama Murthy Gubbala
Independent Director	Mr. Govinda Prasad Dasu
Independent Director	Mr. Umamaheshwarrao Naidu Madireddi
Independent Director	Mr. Venkateswara Rao Thallapaka
Non-Executive Director	Mr. Sridhar Sankararaman
Independent Director	Mrs. Leela Digumarti
6. Relatives of KMP	Mrs. Durga Devi Nannapaneni Dr. N. Ramakrishna Rao Mrs. V S Swathi Kantamani

(b) Related party transactions during the year

	For the year ended	
	31 March 2021	31 March 2020
Time Cap Overseas Limited, Mauritius		
Investment in equity shares	614.77	9.14
Loan given	-	17.76
Interest income on loan	6.95	10.00
Interest received	17.35	-
NATCO Pharma (Canada) Inc., Canada		
Sale of products	539.64	156.11
NATCO Pharma Asia Pte Ltd., Singapore		
Investment in equity shares	-	12.93
Interest income on loan	5.78	5.63
Sale of products	45.89	13.58
Natcofarma Do Brasil Ltda., Brazil		
Sale of products	70.29	281.18
Reimbursement of expenses	0.90	-
Corporate guarantee given	146.74	-
NATCO Pharma Australia Pty Ltd., Australia		
Investment in equity shares	45.79	3.92
NATCO Pharma Inc., United States of America		
Investment in equity shares	120.54	-
Interest income on loan	5.67	6.48
Interest received	13.54	-

For NATCO Pharma Limited


S.V.V.N. APPA RAO
Chief Financial Officer

NATCO Pharma Limited

(All amounts in ₹ millions)

(b) Related party transactions during the year (continued)

	For the year ended	
	31 March 2021	31 March 2020
NATCO Lifesciences Philippines Inc., Philippines		
Investment in equity shares	5.51	24.00
Interest income on loan	-	0.09
Time Cap Pharma Labs Private Limited		
Rental expense	5.40	5.40
NATCO Trust		
Donations	4.50	0.20
Contribution to corporate social responsibility activities	150.03	157.00
Mr. V C Nannapaneni		
Managerial remuneration*	18.50	18.50
Leave encashment paid	0.89	0.89
Rental expense	2.40	2.40
Mr. Rajeev Nannapaneni		
Managerial remuneration*	17.00	17.00
Leave encashment paid	0.81	0.81
Rental expense	3.00	2.64
Mr. P.S.R.K. Prasad		
Managerial remuneration*	23.49	17.82
Leave encashment paid	0.45	0.45
Loan given	9.20	-
Mr. Lingarao Donthineni		
Managerial remuneration*	28.40	17.82
Leave encashment paid	0.45	0.45
Loan given	43.00	-
Mr. S.V.V.N. Appa Rao		
Managerial remuneration*	10.22	9.35
Leave encashment paid	0.23	-
Mr. Adinarayana M		
Managerial remuneration*	5.24	5.06
Leave encashment paid	0.16	-
Sitting fees:		
Mr. Govinda Prasad Dasu	0.44	0.21
Mrs. Leela Digumarti	0.30	0.10
Mr. Umamaheshwarrao Naidu Madireddi	0.54	0.31
Mr. Sreerama Murthy Gubbala	0.60	0.46
Mr. Venkateswara Rao Thallapaka	0.44	0.28

For NATCO Pharma Limited



S.V.V.N. APPA RAO
Chief Financial Officer

NATCO Pharma Limited


(All amounts in ₹ millions)

Related party disclosures, as per Ind AS 24 (continued)**(c) Related party closing balances as on balance sheet date receivable/(payable):**

	As at	
	31 March 2021	31 March 2020
Loan receivable		
NATCO Pharma Inc., United States of America	-	124.39
Time cap Overseas Limited, Mauritius	-	288.73
NATCO Pharma Asia PTE Ltd., Singapore	114.09	110.63
Mr. P.S.R.K. Prasad	3.00	-
Mr. Lingarao Donthineni	34.00	-
Interest receivable on loans		
NATCO Pharma Inc., United States of America	-	8.28
Time cap Overseas Limited, Mauritius	-	10.49
NATCO Pharma Asia PTE Ltd., Singapore	11.14	4.23
Trade receivables		
NATCO Pharma (Canada) Inc., Canada	-	119.23
Natcofarma Do Brasil Ltda., Brazil	161.28	266.29
NATCO Pharma Asia PTE Ltd., Singapore	10.64	8.06
Corporate Guarantee given		
Natcofarma Do Brasil Ltda., Brazil	15.00	-
Advance from customers		
NATCO Pharma (Canada) Inc., Canada	(165.62)	-
Remuneration payable		
Mr. V.C. Nannapaneni	(0.53)	(0.30)
Mr. Rajeev Nannapaneni	(0.17)	(0.60)
Mr. Lingarao Donthineni	(0.27)	(2.73)
Mr. P.S.R.K. Prasad	(0.13)	(2.71)
Mr. S.V.N.N. Appa Rao	(0.03)	(0.07)
Mr. Adinarayana M	(0.03)	(0.12)

*This aforesaid amount does not include amounts in respect of gratuity and compensated absences as the same are determined on actuarial basis for the Company as a whole.

For NATCO Pharma Limited



S.V.V.N. APPA RAO
Chief Financial Officer